SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Shilpa Medicare gets marketing authorization from Portugal for Tadalafil Orodispersible Films

10 Jan 2025 Evaluate

Shilpa Medicare has received Marketing Authorization from Portugal, Europe, for Tadalafil Orodispersible Films, 20 mg. The total Europe market for oral Tadalafil formulations is estimated at about $400 million. Shilpa Medicare becomes the first company in the World to receive approval for this product as a convenient, patient friendly oral mouth dissolving/dispersing Film formulation. This approval is a hybrid application and Shilpa’s product is bioequivalent to the reference product. Tadalafil is indicated for the treatment of erectile dysfunction (sometimes called impotence) in adult males. 

This approval has come from the company’s finished dosage form manufacturing facility, Unit VI, located at Dabaspet, Bengaluru, Karnataka. The facility is currently approved by MHRA UK and this is the second approval for a prescription oral mouth dissolving film product in the European/UK regulated markets from the facility. The facility is involved in manufacturing, packaging, labelling and testing of finished dosage forms (oral dispersible/dissolving Films and Transdermal Patches).  

Shilpa Medicare produces and exports consistently high-quality Active Pharmaceutical Ingredients Fine Chemicals, intermediates, herbal products and speciality chemical products using sophisticated technology, meticulously following international specifications.


Shilpa Medicare Share Price

411.55 0.30 (0.07%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×